Metabolism and fibrosis

Innovative approaches for precision medicine 

Our research platforms enable precision medicine strategies for metabolic and fibrotic diseases: 

• Development of patient-derived cell models to evaluate drug responses 
• Use of organoids and tissue slices for human-like disease modeling 
• Comprehensive profiling of metabolic and fibrotic pathways to identify novel intervention points.

In vitro models 

• Human primary cells (hepatocytes, fibroblasts, adipoctes)
• iPSC-derived cells (cardiomyocytes, fibroblasts)
• Precision-cut tissue slices for liver and lung fibrosis studies
• Organoid models for fibrotic disease pathways.

In vivo efficacy models  

• Evaluation of anti-fibrotic and metabolic interventions in disease-relevant models 
• CCL4- and TAA-induced liver fibrosis models 
• Bleomycin-induced lung fibrosis in mice and rats 
• Diet-induced obesity and diabetes models in rodents 
• Lipid tolerance and glucose metabolism studies  
• PK/PD assessments and dose optimisation.

Analytical platforms and mechanistic studies  

• Seahorse analyser for metabolic flux analysis 
• Advanced imaging systems for tissue fibrosis quantification 
• Proteomics and transcriptomics for biomarker discovery  
• Pathway analysis and mode-of-action characterisation
• Integration of multi-omics data to uncover therapeutic targets.

Tailored services for drug development    

Nuvisan offers a wide range of off-the-shelf pharmacology models tailored to your research needs, while also providing expert customisation support to develop bespoke solutions for your unique scientific challenges. Trust us to adapt our models to meet your specific requirements, helping ensure precision and reliability in your pharmaceutical research.